MASH is the updated term for NASH to decrease stigma and improve understanding. The name change links liver disease to metabolic factors, which improves diagnosis and treatment. Challenges include ...

A form of liver disease which threatens to become a modern epidemic due to its association with obesity and type 2 diabetes – both major health issues for modern society – may be stopped in its tracks ...

The history of drug research in the liver disease non-alcoholic steatohepatitis (NASH) is littered with clinical trial failures, but Akero Therapeutics is now trumpeting a Phase 2 win. Crucially, the ...

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no current cure, but a drug called resmetirom may offer a lifeline for millions of patients, promoting a better quality of life ...

The global therapeutic market catering to the widely prevalent liver disease non-alcoholic steatohepatitis (NASH) is projected to reach $48.3B by 2035, international consulting firm Research Nester ...

Companies in clinical development with drugs for the fatty liver disease NASH are all testing chronic treatments—medicines either injected or taken orally on a regular basis. Gene therapy offers the ...

Liver disease researchers, stumped by a complex disease, are looking for new investigative tools. Artificial intelligence might be one of them. At a small conference of the American Association for ...

Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this ...